Sinusoidal obstruction syndrome natural history, complications and prognosis: Difference between revisions
Line 19: | Line 19: | ||
==Prognosis== | ==Prognosis== | ||
* Sinusoidal obstruction syndrome is considered mild, moderate or severe based on the clinical course during the first three months of hematopoietic cell transplantation.<ref name="pmid8420443">{{cite journal |vauthors=McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA |title=Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients |journal=Ann. Intern. Med. |volume=118 |issue=4 |pages=255–67 |year=1993 |pmid=8420443 |doi= |url=}}</ref> | * Sinusoidal obstruction syndrome is considered mild, moderate or severe based on the clinical course during the first three months of hematopoietic cell transplantation.<ref name="pmid8420443">{{cite journal |vauthors=McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA |title=Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients |journal=Ann. Intern. Med. |volume=118 |issue=4 |pages=255–67 |year=1993 |pmid=8420443 |doi= |url=}}</ref> | ||
* Patients with a mild or moderate form of sinusoidal obstruction syndrome requires no specific therapy and can be managed with supportive care alone and | * Patients with a mild or moderate form of sinusoidal obstruction syndrome requires no specific therapy and can be managed with supportive care alone and progressively resolves over a 2- to 3-week period.<ref name="pmid25755580">{{cite journal| author=Fan CQ, Crawford JM| title=Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). | journal=J Clin Exp Hepatol | year= 2014 | volume= 4 | issue= 4 | pages= 332-46 | pmid=25755580 | doi=10.1016/j.jceh.2014.10.002 | pmc=4298625 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25755580 }} </ref> | ||
* Patients with the severe sinusoidal obstruction syndrome has a high rate of mortality and can progress to multiorgan failure.<ref name="pmid21383682">{{cite journal |vauthors=Lopes JA, Jorge S |title=Acute kidney injury following HCT: incidence, risk factors and outcome |journal=Bone Marrow Transplant. |volume=46 |issue=11 |pages=1399–408 |year=2011 |pmid=21383682 |doi=10.1038/bmt.2011.46 |url=}}</ref> | * Patients with the severe sinusoidal obstruction syndrome has a high rate of mortality and can progress to multiorgan failure.<ref name="pmid21383682">{{cite journal |vauthors=Lopes JA, Jorge S |title=Acute kidney injury following HCT: incidence, risk factors and outcome |journal=Bone Marrow Transplant. |volume=46 |issue=11 |pages=1399–408 |year=2011 |pmid=21383682 |doi=10.1038/bmt.2011.46 |url=}}</ref> | ||
Morbidity and mortality is associated with following factors:<ref name="pmid8646485">{{cite journal |vauthors=Tabbara IA, Ghazal CD, Ghazal HH |title=Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation |journal=J Hematother |volume=5 |issue=1 |pages=79–84 |year=1996 |pmid=8646485 |doi=10.1089/scd.1.1996.5.79 |url=}}</ref><ref name="pmid9058743">{{cite journal |vauthors=Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E |title=Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation |journal=Blood |volume=89 |issue=6 |pages=2184–8 |year=1997 |pmid=9058743 |doi= |url=}}</ref><ref name="pmid8507881">{{cite journal |vauthors=Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, McDonald GB, Mannucci PM |title=Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver |journal=Blood |volume=81 |issue=12 |pages=3458–62 |year=1993 |pmid=8507881 |doi= |url=}}</ref><ref name="pmid1755004">{{cite journal |vauthors=Scrobohaci ML, Drouet L, Monem-Mansi A, Devergie A, Baudin B, D'Agay MF, Gluckman E |title=Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers |journal=Thromb. Res. |volume=63 |issue=5 |pages=509–19 |year=1991 |pmid=1755004 |doi= |url=}}</ref> | Morbidity and mortality is associated with following factors:<ref name="pmid8646485">{{cite journal |vauthors=Tabbara IA, Ghazal CD, Ghazal HH |title=Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation |journal=J Hematother |volume=5 |issue=1 |pages=79–84 |year=1996 |pmid=8646485 |doi=10.1089/scd.1.1996.5.79 |url=}}</ref><ref name="pmid9058743">{{cite journal |vauthors=Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E |title=Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation |journal=Blood |volume=89 |issue=6 |pages=2184–8 |year=1997 |pmid=9058743 |doi= |url=}}</ref><ref name="pmid8507881">{{cite journal |vauthors=Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, McDonald GB, Mannucci PM |title=Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver |journal=Blood |volume=81 |issue=12 |pages=3458–62 |year=1993 |pmid=8507881 |doi= |url=}}</ref><ref name="pmid1755004">{{cite journal |vauthors=Scrobohaci ML, Drouet L, Monem-Mansi A, Devergie A, Baudin B, D'Agay MF, Gluckman E |title=Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers |journal=Thromb. Res. |volume=63 |issue=5 |pages=509–19 |year=1991 |pmid=1755004 |doi= |url=}}</ref> |
Revision as of 01:33, 7 February 2018
Sinusoidal obstruction syndrome Microchapters |
Differentiating Sinusoidal obstruction syndrome from Other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Sinusoidal obstruction syndrome natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Sinusoidal obstruction syndrome natural history, complications and prognosis |
FDA on Sinusoidal obstruction syndrome natural history, complications and prognosis |
CDC on Sinusoidal obstruction syndrome natural history, complications and prognosis |
Sinusoidal obstruction syndrome natural history, complications and prognosis in the news |
Blogs on Sinusoidal obstruction syndrome natural history, complications and prognosis |
Directions to Hospitals Treating Sinusoidal obstruction syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Patients with a mild or moderate form of sinusoidal obstruction syndrome require no specific therapy and can be managed with supportive care alone and generally has a good prognosis. If left untreated, the severe form of sinusoidal obstruction syndrome is characterized by high mortality and progression to multiorgan failure.
Natural History
- Sinusoidal obstruction syndrome is a common complication in patients with hematopoietic stem cell transplant.
- If left untreated, the severe form of sinusoidal obstruction syndrome is characterized by high mortality and progression to multiorgan failure.[1]
Complications
Complications that can develop as a result of sinusoidal obstruction syndrome are:[2][3][4][5]
- Portal hypertension
- Hepatic encephalopathy
- Variceal hemorrhage
- Hepatorenal syndrome
- Hepatic decompensation
- Bacterial peritonitis especially the following paracentesis
Prognosis
- Sinusoidal obstruction syndrome is considered mild, moderate or severe based on the clinical course during the first three months of hematopoietic cell transplantation.[6]
- Patients with a mild or moderate form of sinusoidal obstruction syndrome requires no specific therapy and can be managed with supportive care alone and progressively resolves over a 2- to 3-week period.[7]
- Patients with the severe sinusoidal obstruction syndrome has a high rate of mortality and can progress to multiorgan failure.[8]
Morbidity and mortality is associated with following factors:[9][10][11][12]
- Younger age in children
- Older age in adults
- Poor performance status
- Pre-existing hepatic dysfunction
- History of pancreatitis
- Advanced malignancy
- Acute leukemia
- Presence of acute graft-versus-host disease
- Allogeneic HCT
- Unrelated donor HCT
- Mismatched donor
- Prior abdominal irradiation
- High dose cytoreductive therapy
- Total body irradiation
References
- ↑ Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A; et al. (2010). "Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome". Biol Blood Marrow Transplant. 16 (2): 157–68. doi:10.1016/j.bbmt.2009.08.024. PMC 3018714. PMID 19766729.
- ↑ Grus T, Lambert L, Grusová G, Banerjee R, Burgetová A (2017). "Budd-Chiari Syndrome". Prague Med Rep. 118 (2–3): 69–80. doi:10.14712/23362936.2017.6. PMID 28922103.
- ↑ Lin M, Zhang F, Wang Y, Zhang B, Zhang W, Zou X, Zhang M, Zhuge Y (2017). "Liver cirrhosis caused by chronic Budd-Chiari syndrome". Medicine (Baltimore). 96 (34): e7425. doi:10.1097/MD.0000000000007425. PMC 5571988. PMID 28834866.
- ↑ Lane ER, Hsu EK, Murray KF (2015). "Management of ascites in children". Expert Rev Gastroenterol Hepatol. 9 (10): 1281–92. doi:10.1586/17474124.2015.1083419. PMID 26325252.
- ↑ Johnson DB, Savani BN (2012). "How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?". Exp Hematol. 40 (7): 513–7. doi:10.1016/j.exphem.2012.04.004. PMID 22542577.
- ↑ McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA (1993). "Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients". Ann. Intern. Med. 118 (4): 255–67. PMID 8420443.
- ↑ Fan CQ, Crawford JM (2014). "Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)". J Clin Exp Hepatol. 4 (4): 332–46. doi:10.1016/j.jceh.2014.10.002. PMC 4298625. PMID 25755580.
- ↑ Lopes JA, Jorge S (2011). "Acute kidney injury following HCT: incidence, risk factors and outcome". Bone Marrow Transplant. 46 (11): 1399–408. doi:10.1038/bmt.2011.46. PMID 21383682.
- ↑ Tabbara IA, Ghazal CD, Ghazal HH (1996). "Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation". J Hematother. 5 (1): 79–84. doi:10.1089/scd.1.1996.5.79. PMID 8646485.
- ↑ Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E (1997). "Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation". Blood. 89 (6): 2184–8. PMID 9058743.
- ↑ Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, McDonald GB, Mannucci PM (1993). "Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver". Blood. 81 (12): 3458–62. PMID 8507881.
- ↑ Scrobohaci ML, Drouet L, Monem-Mansi A, Devergie A, Baudin B, D'Agay MF, Gluckman E (1991). "Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers". Thromb. Res. 63 (5): 509–19. PMID 1755004.